| Drug General Information |
| Drug ID |
D0A5TS
|
| Former ID |
DCL001109
|
| Drug Name |
EVT-101
|
| Drug Type |
Small molecular drug
|
| Indication |
Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Therapeutic Class |
Neurodegenerative
|
| Company |
Roche
|
| Structure |
|
Download
2D MOL
|
| Formula |
C16H15Cl2F3N4
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Antagonist |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Dopaminergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholism
|
|
Systemic lupus erythematosus
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
BDNF signaling pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023880) |
|---|
| REF 2 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. |
|---|
